Today, Laboratorios Farmacéuticos Rovi, S.A. held its Ordinary General Shareholders’ Meeting, at which the year 2021, marked by the company’s historic growth, was evaluated. ROVI achieved a 54% increase in its operating revenue. This increase was principally driven by the strength of the contract manufacturing business, which grew by 189%, and the specialty pharmaceutical business, whose sales rose 17%. “The year 2021 was historic for our company, which reaffirmed its original commitment to global health,” said Mr Juan López-Belmonte Encina, ROVI’s Chairman and Chief Executive Officer.
In his speech, he highlighted the value of the achievements reached in the year, which positioned ROVI as “one of the companies with the greatest knowledge in the low-molecular-heparin field and able to aspire to expand its global presence over the years to come.” Furthermore, in 2021, “ROVI continued to be the leader in specialty pharmaceuticals in Spain, while, as a result of the agreements with Modena, the contract manufacturing business gained a large amount of public visibility, confirming what we had always known: it is a strong driver that will help the company to grow in future years.”
The Chairman and CEO also highlighted “the work and commitment of the group’s employees overall” in reaching milestones that were important to ROVI in the year, such as achieving carbon neutrality for the second consecutive year or obtaining the second best score in the ESG ranking drawn up by the company Sustainalytics.
The Deputy Chairman and Chief Financial Officer, Javier López-Belmonte, provided an update on the R&D strategy of the company, “which is entering into a wonderful new phase after receiving the marketing approval for Europe of our first ISM®-technology-based drug.” He said that “our first large project with this technology, which was patented by ROVI, is a product for schizophrenia, a disease that affects over 21 million people worldwide” and added that “the application for marketing authorisation for Risperidone ISM® in the United States is awaiting the response of the United States regulatory authority.”
